NCT00241462
Terminated
Not Applicable
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
ConditionsBreast Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- AstraZeneca
- Enrollment
- 150
- Locations
- 1
- Status
- Terminated
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Postmenopausal
- •Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status
- •Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment
Exclusion Criteria
- •Life threatening metastases
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in FranceBreast CancerNCT00681369AstraZeneca217
Completed
Not Applicable
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)Malignant Neoplasm of Breast Stage IVNCT01509625Isabel Blancas272
Completed
Not Applicable
Faslodex Specific Clinical Experience InvestigationBreast CancerNCT01501266AstraZeneca660
Completed
Not Applicable
Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast CancerBreast CancerNCT00878930AstraZeneca500
Completed
Phase 2
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerMetastatic Breast CancerNCT00274469AstraZeneca205